A research letter reported that robust secretion of SARS-CoV-2 specific IgA and IgG antibodies were found in breast milk of breastfeeding women for 6 weeks after the first of 2 vaccinations against COVID-19.
Robust secretion of SARS-CoV-2 specific IgA and IgG antibodies were found in breast milk of breastfeeding women for 6 weeks after the first of 2 vaccinations against COVID-19, according to a research letter in JAMA.
The prospective study from Israel also concluded that IgA secretion was evident as early as 2 weeks after vaccination, followed by a spike in IgG after 4 weeks, or the equivalent of 1 week after the second vaccine.
“Israel was among the first countries to undertake a nationwide vaccination program against COVID-19,” said principal investigator Ilan Youngster, MD, MMSc, director of pediatric infectious diseases at Shamir Medical Center in Zerifin, Israel. “Initially, high-risk groups were targeted, including healthcare personnel, many of whom are women with young infants at home.”
As a result, Youngster and his colleagues promptly received a barrage of questions about the safety of being vaccinated while breastfeeding, and any potential benefit to the baby.
“On a national level, it was decided that in spite of the lack of information, breastfeeding women should be vaccinated,” Youngster told Contemporary OB/GYN®. “Thus, we decided to conduct a study to examine whether anti-SARS-CoV-2 antibodies are secreted into breastmilk, and whether any infant adverse events are described.”
Continue reading this article on Contemporary OBGYN
Socioeconomic Disparities Persisted Alongside Improving Vaccination Rates In US Over 11-Year Period
April 16th 2024Findings indicating that socioeconomic disparities widened gaps in vaccination timeliness signal the need for increased efforts to promote timely vaccination among children from families with lower income and those without private insurance.
Pfizer Announces Positive Top-Line Data for Abrysvo Immunization in Adults Aged 18 to 59 Years
April 9th 2024Abrysvo is currently approved to treat RSV-associated lower respiratory tract disease in adults aged 60 years and older, and in infants through the immunization of pregnant individuals.